Cargando…

A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition

Proton pump inhibitors (PPIs) are among the most prescribed and widely used medications; however, the long-term effects of these medications are only beginning to be investigated. Since the introduction of omeprazole in 1989, PPIs have become the first-choice treatment for esophagitis, peptic ulcer...

Descripción completa

Detalles Bibliográficos
Autores principales: McMillan, Alexandra, Perez, Christopher, Brooks, Amanda E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519524/
https://www.ncbi.nlm.nih.gov/pubmed/37746961
http://dx.doi.org/10.1097/MD.0000000000035351
_version_ 1785109718873669632
author McMillan, Alexandra
Perez, Christopher
Brooks, Amanda E.
author_facet McMillan, Alexandra
Perez, Christopher
Brooks, Amanda E.
author_sort McMillan, Alexandra
collection PubMed
description Proton pump inhibitors (PPIs) are among the most prescribed and widely used medications; however, the long-term effects of these medications are only beginning to be investigated. Since the introduction of omeprazole in 1989, PPIs have become the first-choice treatment for esophagitis, peptic ulcer disease, Zoster–Ellison syndrome, dyspepsia, and the prevention of ulcers with non-steroidal anti-inflammatory drugs. Recent studies have specifically examined the rise in celiac disease (CD) in this context. This review explores how PPIs may impact the development of CD and highlights the need for additional research into the environmental and genetic factors that influence the development and progression of the disease. A literature search was performed using the keywords celiac disease, proton pump inhibitors, human leukocyte antigen (HLA)-DQ2, HLA-DQ8. The pathogenesis of CD is multifactorial, and human leukocyte antigens are one factor that may contribute to its development. Additionally, pharmaceuticals, such as PPIs, that cause gut dysbiosis have been linked to the inflammatory response present in CD. Recent studies have suggested that the rise in CD could be attributed to changes in the gut microbiome, highlighting the significant role that gut microbiota is proposed to play in CD pathogenesis. Although PPI therapy is helpful in reducing acid production in gastroesophageal disorders, additional information is needed to determine whether PPIs are still an appropriate treatment option with the possibility of developing CD in the future, particularly in the context of HLA-DQ2 and HLA-DQ8 predispositions. This review emphasizes the importance of personalized medicine for individuals with gastroesophageal disorders that require long-term use of PPIs.
format Online
Article
Text
id pubmed-10519524
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105195242023-09-26 A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition McMillan, Alexandra Perez, Christopher Brooks, Amanda E. Medicine (Baltimore) 4500 Proton pump inhibitors (PPIs) are among the most prescribed and widely used medications; however, the long-term effects of these medications are only beginning to be investigated. Since the introduction of omeprazole in 1989, PPIs have become the first-choice treatment for esophagitis, peptic ulcer disease, Zoster–Ellison syndrome, dyspepsia, and the prevention of ulcers with non-steroidal anti-inflammatory drugs. Recent studies have specifically examined the rise in celiac disease (CD) in this context. This review explores how PPIs may impact the development of CD and highlights the need for additional research into the environmental and genetic factors that influence the development and progression of the disease. A literature search was performed using the keywords celiac disease, proton pump inhibitors, human leukocyte antigen (HLA)-DQ2, HLA-DQ8. The pathogenesis of CD is multifactorial, and human leukocyte antigens are one factor that may contribute to its development. Additionally, pharmaceuticals, such as PPIs, that cause gut dysbiosis have been linked to the inflammatory response present in CD. Recent studies have suggested that the rise in CD could be attributed to changes in the gut microbiome, highlighting the significant role that gut microbiota is proposed to play in CD pathogenesis. Although PPI therapy is helpful in reducing acid production in gastroesophageal disorders, additional information is needed to determine whether PPIs are still an appropriate treatment option with the possibility of developing CD in the future, particularly in the context of HLA-DQ2 and HLA-DQ8 predispositions. This review emphasizes the importance of personalized medicine for individuals with gastroesophageal disorders that require long-term use of PPIs. Lippincott Williams & Wilkins 2023-09-22 /pmc/articles/PMC10519524/ /pubmed/37746961 http://dx.doi.org/10.1097/MD.0000000000035351 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4500
McMillan, Alexandra
Perez, Christopher
Brooks, Amanda E.
A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition
title A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition
title_full A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition
title_fullStr A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition
title_full_unstemmed A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition
title_short A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition
title_sort review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of hla-dq2 and hla-dq8 genetic predisposition
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519524/
https://www.ncbi.nlm.nih.gov/pubmed/37746961
http://dx.doi.org/10.1097/MD.0000000000035351
work_keys_str_mv AT mcmillanalexandra areviewofthelongtermuseofprotonpumpinhibitorsandriskofceliacdiseaseinthecontextofhladq2andhladq8geneticpredisposition
AT perezchristopher areviewofthelongtermuseofprotonpumpinhibitorsandriskofceliacdiseaseinthecontextofhladq2andhladq8geneticpredisposition
AT brooksamandae areviewofthelongtermuseofprotonpumpinhibitorsandriskofceliacdiseaseinthecontextofhladq2andhladq8geneticpredisposition
AT mcmillanalexandra reviewofthelongtermuseofprotonpumpinhibitorsandriskofceliacdiseaseinthecontextofhladq2andhladq8geneticpredisposition
AT perezchristopher reviewofthelongtermuseofprotonpumpinhibitorsandriskofceliacdiseaseinthecontextofhladq2andhladq8geneticpredisposition
AT brooksamandae reviewofthelongtermuseofprotonpumpinhibitorsandriskofceliacdiseaseinthecontextofhladq2andhladq8geneticpredisposition